|
Aug 1
|
WuXi Biologics' Four Manufacturing Facilities and Biosafety Testing Center Certified Again by European Medicines Agency for Ten Biologics
|
|
Mar 26
|
WuXi Biologics Reports Solid 2023 Annual Results
|
|
Jan 26
|
Chinese Biotech Stocks Plunge on Proposed U.S. Legislation
|
|
Jan 26
|
US lawmaker moves bill to ban Chinese biotech firms from federal contracts, alleging complicity with military
|
|
Jan 26
|
WuXi AppTec, Wuxi Bio Tumble as US Lawmakers Propose Ban
|
|
Jan 25
|
WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect
|
|
Jan 17
|
WuXi Biologics Granted U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™
|
|
Jan 10
|
WuXi Biologics Announces Research Service Agreement with BioNTech on Discovering Investigational Monoclonal Antibodies for Developing Next-Generation Therapeutic Product Candidates
|
|
Dec 12
|
WuXi Biologics Named to 2023 Dow Jones Sustainability World Index
|
|
Dec 8
|
WuXi Biologics Awarded Highest Platinum Medal by EcoVadis Sustainability Rating
|
|
Dec 5
|
China biotech: investors fear a negative reaction from the US
|
|
Nov 8
|
WuXi Biologics Receives AAA MSCI ESG Rating
|
|
Nov 7
|
Hong Kong IPO: WuXi Biologics to spin off contract research, manufacturing unit via US$520 million deal in biotech push
|
|
Aug 11
|
WuXi Biologics and Boostimmune Sign MOU for Exclusive Research and Discovery Services
|